{"id":"dexamethasone-for-control-of-symptoms","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Adrenal suppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory mediators. These effects result in broad anti-inflammatory and immunosuppressive actions that control symptoms across multiple conditions.","oneSentence":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:13.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Symptom control in inflammatory and autoimmune conditions"},{"name":"Symptom management in conditions requiring immunosuppression"}]},"trialDetails":[{"nctId":"NCT07100990","phase":"PHASE3","title":"Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-11","conditions":"Optic Neuritis, Myelitis, Myelitis, Transverse","enrollment":382},{"nctId":"NCT06930690","phase":"PHASE1, PHASE2","title":"Dexamethasone for Ureteral STent Symptoms (DUSTS)","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Ureteral Stent-Related Symptom","enrollment":70},{"nctId":"NCT07334379","phase":"PHASE2","title":"Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study","status":"RECRUITING","sponsor":"Lorenzo delSorbo","startDate":"2025-10-20","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":60},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT04697940","phase":"PHASE1, PHASE2","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han weidong","startDate":"2021-04-15","conditions":"Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells","enrollment":33},{"nctId":"NCT04461418","phase":"PHASE2","title":"Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2021-03-30","conditions":"Brain Metastases, Adult","enrollment":2},{"nctId":"NCT05773950","phase":"NA","title":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","status":"ENROLLING_BY_INVITATION","sponsor":"Samsung Medical Center","startDate":"2023-08-18","conditions":"Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy","enrollment":144},{"nctId":"NCT04879823","phase":"PHASE3","title":"Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity","status":"TERMINATED","sponsor":"David Chi, MD","startDate":"2021-08-05","conditions":"Adenotonsillectomy, Analgesia, Surgery","enrollment":222},{"nctId":"NCT05814757","phase":"PHASE2","title":"OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2023-05-11","conditions":"Dry Eye Syndromes, Eye Diseases","enrollment":100},{"nctId":"NCT04876612","phase":"NA","title":"Effect of Limaprost in Combination With Transforaminal Epidural Steroid Injection","status":"RECRUITING","sponsor":"Seoul National University","startDate":"2021-11-10","conditions":"Lumbar Spinal Stenosis","enrollment":104},{"nctId":"NCT02770807","phase":"PHASE3","title":"Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2017-03-02","conditions":"Nervous System Disease, Genetic Syndrome","enrollment":176},{"nctId":"NCT02305173","phase":"PHASE3","title":"Dexamethasone and Respiratory Function After Mastectomy","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2014-11","conditions":"Respiratory; Disorder, Functional, Impaired","enrollment":120},{"nctId":"NCT04465071","phase":"NA","title":"Lubricating Eye Drops After Routine Cataract Surgery","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2020-02-24","conditions":"Dry Eye, Cataract","enrollment":79},{"nctId":"NCT01248585","phase":"PHASE3","title":"Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2011-05-30","conditions":"Bone Metastases","enrollment":298},{"nctId":"NCT05631912","phase":"PHASE1, PHASE2","title":"TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2023-06-30","conditions":"Non-hodgkin Lymphoma,B Cell","enrollment":38},{"nctId":"NCT04854824","phase":"","title":"A Simple Approach to Prevent Hospitalization for COVID-19 Patients","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-07-01","conditions":"Covid19","enrollment":216},{"nctId":"NCT04747977","phase":"PHASE2","title":"To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2021-02-12","conditions":"Dry Eye","enrollment":172},{"nctId":"NCT03495414","phase":"","title":"Neurobiological Underpinnings to Hypersexual Disorder","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2018-04-01","conditions":"Hypersexuality, Hypersexual Disorder, Compulsive Sexual Behavior","enrollment":42},{"nctId":"NCT05258461","phase":"NA","title":"An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-03-07","conditions":"Breast Cancer","enrollment":108},{"nctId":"NCT04359095","phase":"PHASE2, PHASE3","title":"Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2020-08-18","conditions":"COVID-19","enrollment":650},{"nctId":"NCT04746430","phase":"PHASE4","title":"COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study","status":"TERMINATED","sponsor":"General Practitioners Research Institute","startDate":"2021-02-16","conditions":"Covid19, Corona Virus Infection","enrollment":17},{"nctId":"NCT04131335","phase":"NA","title":"Use of Prophylactic Lubricating Drops After Cataract Surgery","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2019-10-14","conditions":"Dry Eye, Cataract Surgery, Patient Related Outcome Measures","enrollment":168},{"nctId":"NCT01135550","phase":"PHASE3","title":"Low Dose Versus Usual Dose Dexamethasone for Symptom Control in Children Undergoing Cranial or Craniospinal Radiation","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2010-06","conditions":"Vomiting, Headache","enrollment":25},{"nctId":"NCT01332812","phase":"PHASE4","title":"Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-01","conditions":"Postoperative Cognitive Dysfunction","enrollment":300},{"nctId":"NCT01326585","phase":"PHASE4","title":"Study Trial of Dexamethasone Use for Alleviation of Symptoms After Scleral Buckle Eye Surgery","status":"WITHDRAWN","sponsor":"University of Toronto","startDate":"2011-04","conditions":"Retinal Detachment","enrollment":""},{"nctId":"NCT02288078","phase":"PHASE2","title":"Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)","status":"UNKNOWN","sponsor":"Clinical Research Support Center Kyush","startDate":"2014-10","conditions":"Rectal Cancer","enrollment":74},{"nctId":"NCT02288741","phase":"PHASE3","title":"Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy","status":"COMPLETED","sponsor":"WiSP Wissenschaftlicher Service Pharma GmbH","startDate":"2001-08","conditions":"Multiple Myeloma","enrollment":549},{"nctId":"NCT00088166","phase":"PHASE3","title":"XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors","status":"COMPLETED","sponsor":"Celtic Pharma Development Services","startDate":"2004-05","conditions":"Brain Edema, Brain Tumor","enrollment":200},{"nctId":"NCT00623766","phase":"PHASE2","title":"Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Melanoma","enrollment":99},{"nctId":"NCT01116713","phase":"PHASE3","title":"Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2009-06","conditions":"Postoperative Pain, Postoperative Nausea, Postoperative Vomiting","enrollment":70},{"nctId":"NCT00226668","phase":"PHASE3","title":"XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema","status":"WITHDRAWN","sponsor":"Celtic Pharma Development Services","startDate":"2006-01","conditions":"Brain Edema, Brain Tumor","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["dexamethasone"],"phase":"phase_3","status":"active","brandName":"Dexamethasone for control of symptoms","genericName":"Dexamethasone for control of symptoms","companyName":"WiSP Wissenschaftlicher Service Pharma GmbH","companyId":"wisp-wissenschaftlicher-service-pharma-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Symptom control in inflammatory and autoimmune conditions, Symptom management in conditions requiring immunosuppression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}